GLP1 Europe › Access

Prescription access to GLP-1 medicines in Europe

Last checked 14 August 2026 · About 10 minutes to read · This page dates faster than the others

The two-stage system

Stage one is European. The European Medicines Agency assesses the science and the European Commission grants a marketing authorisation valid in every member state simultaneously. This answers one question only: may this medicine be sold at all. When the Commission approved the Wegovy tablet on 15 July 2026, it became legally sellable across the whole EU that day.

Stage two is national. Each country decides independently whether public money pays, at what price, for which patients, and with what restrictions on who may prescribe. The EU has no power here. A Health Technology Assessment Regulation took effect in January 2025, but it harmonises only the clinical half of the assessment. The economics and the decision stay national.

The distinction that most pages get wrong

Before the country table, one thing has to be clear, because without it none of the rest makes sense.

Reimbursement depends on the diagnosis, not the molecule. Semaglutide prescribed for type 2 diabetes and semaglutide prescribed for obesity are, in most European systems, treated as completely different propositions. The same pharmacy can dispense the same active substance on the same day, covered under one code and entirely self-funded under another.

The reason is structural. Type 2 diabetes is a long-established reimbursable disease with decades of treatment pathways behind it. Obesity, in most European statutes, is either not classified as a disease requiring drug treatment or is explicitly carved out as a lifestyle matter.

So when you read that a country "covers Ozempic", check which indication is meant. It is almost always diabetes.

Country by country

Reimbursement here means for an obesity diagnosis. Where we could not verify an out-of-pocket figure from a non-commercial source, we have left it blank rather than guess.

What changed in France, and why it matters

Almost every English-language page on this subject still says that no European country reimburses GLP-1 medicines for obesity. That stopped being true on 15 June 2026.

France now reimburses both Wegovy and Mounjaro for obesity itself, at 65 percent, under conditions that are deliberately narrow:

• BMI of 40 or above, or 35 or above with at least one weight-related condition
• Nutritional management must have been tried and failed, defined as less than 5 percent weight loss over six months
• The first prescription must come from a specialist: endocrinology, diabetology or nutrition within a designated obesity centre, a bariatric surgeon with the relevant qualification, or a specialist formally partnered with an obesity centre. Renewals can then come from any doctor
• A mandatory accompanying form must be shown to the pharmacist at every dispensing, including for patients who were already on treatment before the change

Note the asymmetry even inside France. Mounjaro for type 2 diabetes can be prescribed by any physician. Mounjaro for obesity requires a specialist to start it. Same drug, same country, different gate.

Germany, the clearest case of the split

Germany is worth understanding in detail because it shows the mechanism at its purest, and because it is widely described incorrectly.

Section 34 of German Social Code Book V bars statutory insurance from covering medicines used predominantly for lifestyle purposes, and names weight-loss drugs specifically. The G-BA applied this to Wegovy on 21 March 2024 and to tirzepatide for weight management on 19 September 2024.

The G-BA was explicit that this attaches to the indication and not the substance. Semaglutide products authorised for type 2 diabetes rather than weight regulation, meaning Ozempic and Rybelsus, are unaffected. The same holds for tirzepatide, which remains prescribable at statutory expense for diabetes.

The exclusion is contested. It dates from 2004, before any of this evidence existed, and clinicians have publicly argued it is outdated given the cardiovascular outcome data now available for semaglutide. We could not verify any legislative proposal or court case currently pending to change it.

Are there still shortages?

Largely no, at EU level, as of 14 August 2026. This is a real change from the 2022 to 2024 period and much online coverage has not caught up.

The European Medicines Agency closed the Ozempic shortage entry in January 2026 and the Trulicity entry in February 2026. There is no EMA shortage entry for Wegovy or Mounjaro at all. At its January 2026 meeting, the EMA shortages working party recorded that the situation had significantly improved and that members confirmed stable supply.

Two caveats. Entries for Saxenda and Victoza remain formally open, though Victoza is being withdrawn from the EU and EEA market by the end of 2026, which is a discontinuation rather than a shortage. And an absence of EU-level shortage does not mean every pharmacy has every strength in stock. National registers track that separately and update continuously.

Online prescribing

Telehealth weight-loss prescribing has grown quickly and the regulatory response is furthest developed in the United Kingdom.

A General Pharmaceutical Council review published on 24 April 2026 found common failings: inconsistent independent verification of height and weight to establish BMI, and incomplete consultation records. The GPhC now requires independent verification of BMI, individual clinical review, documented reasoning, due diligence on third-party prescribing services, ongoing follow-up, and specific care around vulnerable groups including people with eating disorders.

Critically, a self-completed questionnaire is not sufficient. A two-way dialogue must take place before supply, and an independent prescriber must review it rather than an algorithm.

At EU level the emphasis has been on illegal sellers rather than legitimate telehealth. The joint EMA and Heads of Medicines Agencies warning of 3 September 2025 described a sharp rise in illegal medicines marketed as GLP-1 agonists, sold through fraudulent websites and social media, with hundreds of fake profiles and listings identified. We could not verify a national rule in any major EU country specifically restricting remote GLP-1 prescribing, although France achieves a similar effect indirectly through its specialist-initiation and paper-form requirements.

Is there a generic or compounded semaglutide?

No, and European rules here are much stricter than American ones.

Novo Nordisk's European compound patent expired in March 2026, but a supplementary protection certificate extends protection on semaglutide to 19 March 2031. So any "generic semaglutide" offered to a European consumer today is an illegal import, a falsified product, or a compounded preparation of contested legality.

On compounding, Europe never had an equivalent of the United States outsourcing-facility regime that allowed industrial-scale compounded semaglutide. EU law exempts only two narrow things: a preparation made in a pharmacy for one named patient on one prescription, and a preparation made per pharmacopoeia for that pharmacy's own patients. A 2026 Court of Justice ruling confirmed that member states may impose their own additional national restrictions on these, and the Netherlands caps one such route at 50 patients per month.

Enforcement is active. On 5 August 2026 the Hague District Court granted Novo Nordisk a preliminary injunction stopping the sale of a compounded semaglutide nasal spray, holding that resale to other pharmacies fell outside the pharmacy exemption entirely.

Common questions

Can I get a prescription in one EU country and fill it in another?

Cross-border prescription recognition exists in EU law, but reimbursement does not travel with it, and national rules on which prescribers may initiate treatment still apply. In practice this is more complicated than it sounds and depends on both countries involved.

Why is the same drug so much cheaper in some countries?

Because prices are negotiated nationally, and each country negotiates from its own budget and its own reference pricing rules. Manufacturers also adjust prices market by market. Eli Lilly raised UK prices sharply in September 2025; Novo Nordisk cut prices in some markets in February 2026.

How current is this page?

Checked on 14 August 2026 and expected to age quickly. France's rules are weeks old and were already amended once. The Netherlands has a live reassessment, Estonia has one due in autumn 2026, and Sweden may face an appeal. Prices move constantly. Check the date at the top before relying on anything here.

Sources

1. Regulation (EU) 2021/2282 on health technology assessment, applying from 12 January 2025.
2. European Commission and Novo Nordisk, EU approval of the Wegovy tablet and 7.2 mg pen, 15 July 2026.
3. G-BA press release on semaglutide under section 34(1) SGB V, 21 March 2024; and on tirzepatide, 19 September 2024.
4. Assurance Maladie (ameli.fr) and Vidal, on the reimbursement of Wegovy and Mounjaro for obesity from 15 June 2026; arrêtés of 23 May 2026 as amended 10 June 2026.
5. AIFA guidance on diabetes and obesity medicines, 18 May 2026, and Nota 100.
6. Zorginstituut Nederland, GVS advice on semaglutide for obesity, page updated 21 July 2026.
7. TLV decision refusing Wegovy inclusion in the high-cost ceiling, 23 February 2026.
8. Lægemiddelstyrelsen, decision on general clausulated reimbursement for Wegovy, 10 July 2025.
9. AOTMiT Recommendation 70/2026, 21 May 2026.
10. Tervisekassa and Ravimiamet statements on semaglutide reimbursement and prescribing in Estonia, December 2025 and June 2026.
11. NHS England interim commissioning guidance for NICE TA1026, tirzepatide.
12. European Medicines Agency shortages catalogue entries for Ozempic, Trulicity, Saxenda and Victoza, checked 14 August 2026; and Medicine Shortages SPOC Working Party meeting summary, 20 January 2026.
13. General Pharmaceutical Council, review of online weight management services, 24 April 2026.
14. EMA and Heads of Medicines Agencies, warning on illegal medicines sold in the EU, 3 September 2025.
15. District Court of The Hague, preliminary injunction concerning compounded semaglutide, 5 August 2026.

This page describes reimbursement and prescribing rules as published by national authorities on the date shown. Rules change frequently and this page will lag them. It is not medical advice and not a guide to obtaining medicines. For your own situation, speak to a doctor or pharmacist in your country.